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ABSTRACT: In this study, we report an innovative approach
aiming to assess the binding aﬃnity between drug molecules
and human serum albumin by combining nanoporous anodic
alumina rugate ﬁlters (NAA-RFs) modiﬁed with human serum
albumin (HSA) and reﬂectometric interference spectroscopy
(RIfS). NAA-RFs are photonic crystal structures produced by
sinusoidal pulse anodization of aluminum that present two
characteristic optical parameters, the characteristic reﬂection
peak (λPeak), and the eﬀective optical thickness of the ﬁlm
(OTeff), which can be readily used as sensing parameters. A
design of experiments strategy and an ANOVA analysis are
used to establish the eﬀect of the anodization parameters (i.e.,
anodization period and anodization oﬀset) on the sensitivity of
HSA-modiﬁed NAA-RFs toward indomethacin, a model drug. To this end, two sensing parameters are used, that is, shifts in the
characteristic reﬂection peak (ΔλPeak) and changes in the eﬀective optical thickness of the ﬁlm (ΔOTeff). Subsequently, optimized
NAA-RFs are used as sensing platforms to determine the binding aﬃnity between a set of drugs (i.e., indomethacin, coumarin,
sulfadymethoxine, warfarin, and salicylic acid) and HSA molecules. Our results verify that the combination of HSA-modiﬁed
NAA-RFs with RIfS can be used as a portable, low-cost, and simple system for establishing the binding aﬃnity between drugs and
plasma proteins, which is a critical factor to develop eﬃcient medicines for treating a broad range of diseases and medical
conditions.
I n the past decade, the discovery of new drugs andtherapeutic agents has yielded outstanding improvements
in quality of life, health, and life expectancy.1,2 These signiﬁcant
advancements made by pharmaceutical research and innovation
have resulted in drug discoveries that can address or minimize
the eﬀects associated with a broad range of diseases and
medical conditions, including chronic pain, arthritis, cancer,
metabolic and gastrointestinal disorders, infectious and
cardiovascular diseases, and mental disorders.3,4 One key factor
playing a critical role in this innovation-driven progress is to
understand the underlying mechanisms in drug eﬃcacy and
failure. For instance, pharmacokinetics (i.e., the fate of
substances administered externally to a living organism) of
drugs and medicaments is a critical aspect to take into account
in the design of eﬀective therapeutics.5,6 Most of the drugs bind
reversibly to plasma proteins present in the serum and blood
such as glycoprotein and human serum albumin (HSA).
Therefore, the aﬃnity of medicaments toward these proteins is
of critical importance to determine the overall pharmacokinetic
proﬁle of any therapeutic substance. Clinical patients present
diﬀerent levels of these proteins, which in turn makes the free
concentration of drug patient-dependent. As a result, the
therapeutic eﬀect of medicaments with high aﬃnity toward
these circulating proteins could have a signiﬁcant variance as a
function of the levels of these biomolecules. This phenomenon
can also extend the activity of a given drug for a longer time
period given that the complexes formed between medicaments
and proteins can replenish the concentration of free drug as this
is removed from the body. Hence, establishment of the aﬃnity
between drugs and circulating proteins is a critical factor to
consider in the design and assessment of medicines.
Although the drug−protein aﬃnity should be established on
a patient-by-patient basis using serum or blood samples, some
analytical techniques can provide an accurate estimation of this
binding aﬃnity by using simple molecules such as HSA. These
simpliﬁed analyses can be readily used to design more eﬀective
therapeutics in a time-eﬀective and cost-competitive manner,
when many compounds must be screened. Some of these
analytical methods have been extensively used by pharmaceut-
ical industry, including ultraﬁltration, centrifugation, size
exclusion and aﬃnity chromatography, dialysis, spectroscopy,
electrophoresis, and surface plasmon resonance (SPR).7−9
Most of these analytical techniques are based on changes in
intrinsic parameters of molecules and complexes (e.g.,
spectroscopic signature, mobility, charge, etc.) or on separation
processes. Among the diﬀerent alternative techniques, reﬂecto-
metric interference spectroscopy (RIfS) has demonstrated
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outstanding capabilities and versatility for diﬀerent sensing
applications.10,11 RIfS is a label-free optical sensing technique
that relies upon the multiple reﬂection of white light at the
interfaces of solid thin ﬁlms.12,13 As a result of this light−matter
interaction, constructive and destructive interferences of the
reﬂected light form a characteristic interference pattern by the
Fabry−Peŕot eﬀect.14,15 These interferences can be used as
sensing principle to detect analytes of interest in real-time, with
precision. The analytical use of RIfS was pioneered by Gauglitz
and co-workers, who used solid ﬁlms based on glass and
biopolymers with a sensitive layer (i.e., layer where the binding
events between analyte and capturing molecules occur).16
Sailor and co-workers exploited the combination of RIfS with
porous silicon photonic crystals, which are photonic structures
that can guide, reﬂect, conﬁne, and transmit light in a selective
manner by engineering their nanoporous structure.17,18
Recently, we have also demonstrated and exploited the
combination of RIfS with nanoporous anodic alumina (NAA)
photonic crystals, which are produced by electrochemical
oxidation (i.e., anodization) of aluminum substrates.19−24
Figure 1. Concept of sinusoidal pulse anodization approach used to produce nanoporous anodic alumina rugate ﬁlters. (a) Example of sinusoidal
anodization wave with TP = 750 s used to fabricate NAA-RFs (left, deﬁnition of anodization parameters: TP = anodization period, AJ = anodization
amplitude, JOffset = anodization oﬀset, JMax = current density maximum, and JMin = current density minimum; left, example of anodization proﬁle with
insets showing details of the current density and voltage proﬁles). (b) Schematic illustration of the conversion of aluminum substrates into NAA-RFs
by sinusoidal pulse anodization and graphical deﬁnition of period length (LTp). (c) Representative cross-section and top view SEM images of NAA-
RFs produced by sinusoidal pulse anodization approach [left, general cross-section view SEM image of a NAA-RF produced with Tp = 750 s, AJ =
0.42 mA cm−2, JOffset = 0.28 mA cm
−2, NP = 150 pulses, TAn = −1 °C, and tpw = 6 min (scale bar = 2 μm), where CA and SPA denote the layers
produced at constant and sinusoidal pulse anodization modes, respectively; center, magniﬁed view of part a (scale bar = 500 nm); right, top view
SEM image of a NAA-RF (scale bar = 250 nm)].
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Nanoporous photonic crystals present a set of advantages over
their solid counterparts: namely, (i) nanopores that can
accommodate capturing molecules, increasing the speciﬁc
surface area for sensing, (ii) nanopores that can act as physical
ﬁlters to separate analytes, and (iii) ability to engineer the
interaction light matter to enhance the sensing perform-
ance.25,26 The pore geometry of NAA can be precisely
engineered by diﬀerent electrochemical approaches. Therefore,
the eﬀective medium of this nanoporous material can be
rationally engineered in order to create a set of photonic crystal
structures such as distributed Bragg reﬂectors, optical micro-
cavities, waveguides, Fabry−Peŕot interferometers, and rugate
ﬁlters, which are the base of a broad range of optical sensing
systems.27−39 Among these photonic crystal structures, rugate
ﬁlters (RFs) are of special interest given that their optical
spectrum features a well-resolved intense characteristic
reﬂection peak. When the eﬀective medium of a NAA-RF is
modiﬁed, its characteristic reﬂection peak undergoes shifts that
can be used as sensing principle to detect analytes of interest or
establish kinetic parameters associated with biological binding
events. Recently, we reported on an innovative anodization
approach, so-called sinusoidal pulse anodization, aimed at
producing NAA-RFs with ﬁnely tuned photonic properties.40
Herein, we assess and establish the binding aﬃnity between a
set of drugs and HSA by combining HSA-modiﬁed NAA-RFs
with RIfS. First, the nanoporous structure of NAA-RFs is
systematically optimized by evaluating the binding aﬃnity
between HSA-modiﬁed NAA-RFs and indomethacin, a model
drug. NAA-RFs are optimized following a design of experi-
ments (DoE) approach as a function of two fabrication
parameters (i.e., anodization period and anodization oﬀset)
focusing on maximizing the sensitivity on the sensor perform-
ance. Finally, the most sensitive HSA-modiﬁed NAA-RF
structures are used as optical platforms combined with RIfS
to establish the binding aﬃnity between HSA as proof of the
versatility of this system to be used as a generic device for
establishing protein binding aﬃnity.
■ EXPERIMENTAL SECTION
Materials. High-purity (99.9997%) 1.5 × 1.5 cm2 square
aluminum (Al) substrates 0.32 mm thick were supplied by
Goodfellow Cambridge Ltd. (UK). Sulfuric acid (H2SO4),
phosphoric acid (H3PO4), perchloric acid (HClO4), hydro-
chloric acid (HCl), copper(II) chloride (CuCl2), (3-
aminopropyl)triethoxysilane (APTES), hydrogen peroxide
(H2O2), glutaraldehyde (GTA, C5H8O2), human serum
albumin (HSA), phosphate buﬀered saline (PBS), indometha-
cin (C19H16ClNO4), coumarin (C9H6O2), sulfadymethoxine
(C12H14N4O4S), warfarin (C19H16O4), salicylic acid (C7H6O3),
and ethanol (EtOH, C2H5OH) were purchased from Sigma-
Aldrich (Australia) and used as received, without further
puriﬁcation. All the aqueous solutions used in this study were
prepared using ultrapure water Option Q-Purelabs (Australia).
Fabrication of Nanoporous Anodic Alumina Rugate
Filters. NAA-RFs were fabricated following a sinusoidal pulse
anodization approach under mild conditions and galvanostatic
mode (i.e., current density control) in sulfuric acid electrolyte.40
A deﬁnition of the diﬀerent parameters of the sinusoidal
anodization waves used in our study and a representative
anodization proﬁle used to produce NAA-RFs photonic crystal
structure are shown in Figure 1a. Prior to anodization, Al
substrates were cleaned under sonication in ethanol (EtOH)
and distilled water for 15 min each and ﬁnally dried under air
stream. Subsequently, Al substrates were electropolished using
a mixture of HClO4 and EtOH 1:4 (v:v) at 20 V and 5 °C for 3
min. After electropolishing, Al substrates were anodized in a
thermally isolated custom-built anodization reactor using an
aqueous solution 1.1 M sulfuric acid, the temperature of which
was kept at −1 °C throughout the whole process. The
anodization process started with a ﬁrst stage at constant current
density of 1.12 mA cm−2 for 1 h. Then, the sinusoidal pulse
mode was set in order to engineer the eﬀective medium of
NAA in depth (Figure 1b). During this process, the anodization
current density was modiﬁed in a sinusoidal fashion between
high (JMax = 1.12 mA cm
−2) and low (JMin = JOffset = 0.28 mA
cm−2) values according to eq 1:














Here J(t) is the current density at a given time t, AJ is the
current density amplitude, TP is the anodization period, and
JOffset is the current density oﬀset (see Figure 1a).
It is worth noting that the nanoporous layer created during
the ﬁrst stage of this process was used as a shuttle to achieve a
homogeneous pore growth before setting anodization to
sinusoidal mode. Furthermore, the electrolyte solution was
modiﬁed with 25 v% of EtOH in order to prevent it from
freezing at temperatures below 0 °C.41,42 Finally, the pore size
of NAA-RFs was widened by wet chemical etching in an
aqueous solution 5 wt % H3PO4 at 35 °C for 6 min. This
enlargement of the pore size made possible the ﬂow of HSA
molecules inside the nanopores of NAA-RFs in order to create
the desired surface chemistry for drug binding aﬃnity
assessment. Note that these photonic crystals were coated
with a thin ﬁlm of gold of 5 nm using a sputter coater equipped
with ﬁlm thickness monitor (sputter coater 108auto,
Cressington) in order to enhance the interference eﬀect and
enhance the RIfS signal for sensing experiments.43,44
Furthermore, the underlying aluminum substrate was chemi-
cally removed in a saturated solution of HCl/CuCl2 using an
etching cell with a window of 8 mm in diameter.
Optical Characterization. Shifts in the characteristic
reﬂection peak position (ΔλPeak) and changes in the eﬀective
optical thickness (ΔOTeff) of HSA-modiﬁed NAA-RFs
produced as a result of the binding with drug molecules were
monitored by a RIfS system composed of a bifurcated optical
probe that focuses white light from a light source (LS-1LL,
Ocean Optics) on the surface of NAA-RFs. The illumination
spot was adjusted to 2 mm in diameter by a lens system (VIS
Collimating Lens, 350−2000 nm, Ocean Optics). The reﬂected
light was collected by the collection ﬁber, which is assembled
around the same optical probe, and directly transferred to a
miniature spectrometer (USB4000+VIS-NIR-ES, Ocean Op-
tics). The reﬂection spectra of NAA-RFs were acquired from
400 to 1000 nm and saved at intervals of 30 s, with an
integration time of 10 ms and 10 average measurements. RIfS
spectra were processed in Igor Pro library (Wavemetrics) in
order to estimate ΔλPeak and ΔOTeff.
Optimization of HSA-Modiﬁed NAA-RFs. Two anodiza-
tion parameters (i.e., anodization period TP and anodization
oﬀset JOffset − k = 2) were systematically modiﬁed in order to
establish the optimization path between the fabrication
parameters and the sensitivity of the NAA-RFs-RIfS system.
TP and JOffset were modiﬁed from 650 to 750 s (ΔTP = 50 s)
and from 0.140 to 0.420 mA cm−2 with ΔJOffset = 0.105 mA
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cm−2, respectively. The rest of the anodization parameters were
kept constant in all these samples [i.e., AJ = 0.42 mA cm
−2 and
number of sinusoidal pulses (NP) = 150 pulses]. Therefore, a
set of nine NAA-RFs (32 = 9) were fabricated following the
aforementioned approach (Table 1). These NAA-RFs were
chemically functionalized in order to determine the most
sensitive HSA-modiﬁed NAA-RF structure toward indometha-
cin molecules as a function of TP and JOffset. In this process,
NAA-RFs were ﬁrst silanized with APTES following a well-
established functionalization process.45,46 Brieﬂy, NAA-RFs
were hydroxylated in H2O2 30 wt % for 10 min at 90 °C in
order to increase the number of hydroxyl groups on the surface
of alumina. Subsequently, hydroxylated NAA-RFs were
modiﬁed with APTES by chemical vapor deposition process
under vacuum at 110 °C for 3 h. After APTES modiﬁcation,
NAA-RFs were washed with ethanol and water, dried under an
air stream, and stored under dry conditions until further use.
Both the immobilization of HSA and the detection of
indomethacin molecules were performed in real-time by RIfS
using an acrylic-based ﬂow cell. Shifts in the characteristic
reﬂection peak position of each NAA-RF (λPeak) and changes in
the eﬀective optical thickness of the whole ﬁlm (OTeff) were
monitored in real-time by RIfS. Five analytical solutions of
indomethacin (1, 2, 3, 4, and 5 mM) were prepared in PBS
modiﬁed with 5 v% EtOH in order to increase the solubility of
this hydrophobic drug. Note that the diﬀerent solutions were
ﬂowed through the ﬂow cell at a constant rate of 100 μL min−1
by a syringe pump (Fusion 200 Touch series, Chemyx Inc.).
Table 1 provides a comprehensive summary of these NAA-RFs
(experimental matrix), the objective of which was to evaluate
Table 1. Summary of the Fabrication Conditions Used To
Produce the Nanoporous Anodic Alumina Rugate Filters
Utilized in This Study To Establish the Binding Aﬃnity
between Drugs and Human Serum Albumin Molecules
JOffset (mA cm
−2)
TP (s) 0.14 0.28 0.42
650 NAA-RF650−0.14 NAA-RF650−0.28 NAA-RF650−0.42
700 NAA-RF700−0.14 NAA-RF700−0.28 NAA-RF700−0.42
750 NAA-RF750−0.14 NAA-RF750−0.28 NAA-RF750−0.42
Figure 2. Tunability of the characteristic period length (LTp) in NAA-RFs by the anodization period (TP) and the anodization oﬀset (JOffset). (a)
Magniﬁed cross-section view SEM images of NAA-RFs produced with Tp = 650, 700, and 750 s and JOffset = 0.14, 0.28, and 0.42 mA cm
−2 (ﬁxed
parameters: AJ = 0.42 mA cm
−2, NP = 150 pulses, TAn = −1 °C, and tpw = 6 min) (scale bars = 500 nm) (note that red arrows in these images denote
the interfaces between consecutive anodization periods, LTp). (b) Digital pictures of these NAA-RFs displaying diﬀerent interferometric colors as a
function of TP and JOffset (note that the underlying aluminum substrate was chemically etched away in a saturated solution of HCl/CuCl2 using an
etching cell with a window of 8 mm in diameter). (c) Linear dependence of LTp on JOffset for TP = 650, 700, and 750 s. (d) Linear dependence of LTp
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the eﬀect of each of these parameters on the photonic
properties and sensitivity (S) of NAA-RFs measured by two
parameters: namely, (i) changes in the position of the
characteristic reﬂection peak (ΔλPeak) and (ii) changes in the
eﬀective optical thickness of the whole NAA-RF (ΔOTeff). We
applied an analysis of variance (ANOVA) for a 3k-factorial
design of experiments (DoE) in order to discern objectively the
eﬀect of TP and JOffset on the studied variable (i.e., S, sensitivity
of HSA-modiﬁed NAA-RFs toward indomethacin mole-
cules).47,48 A DoE strategy makes it possible to optimize the
number of experiments while establishing possible quadratic
eﬀects in the relationship between the anodization parameters
and the sensitivity of the NAA-RFs-RIfS system.
In this study, three null hypotheses were tested by means of
the aforementioned ANOVA test, namely, the following, if αi
and βj quantify the eﬀects of TP and JOffset, respectively.:
(i) H0, αi = 0 (there is no signiﬁcant eﬀect of TP on S);
(ii) H1, βj = 0 (there is no signiﬁcant eﬀect of JOffset on S);
(iii) H2, (α·β)ij = 0 (there is no signiﬁcant eﬀect of the
anodization parameters interaction (i.e., TP·JOffset) on S).
If these hypotheses were rejected, the alternative hypotheses
would be accepted. These alternative hypotheses are the
following:
(i*) H0*, αi ≠ 0 (there is a signiﬁcant eﬀect of TP on S);
(ii*) H1*, βj ≠ 0 (there is a signiﬁcant eﬀect of JOffset on S);
(iii*) H2*, (α·β)ij ≠ 0 (there is a signiﬁcant eﬀect of the
anodization parameters interaction (i.e., TP·JOffset) on S).
Establishment of Binding Aﬃnity between Drugs and
HSA-Modiﬁed NAA-RFs by RIfS. A set of the most sensitive
NAA-RF structures for each of the aforementioned sensing
parameters (i.e., ΔλPeak and ΔOTeff) toward indomethacin
molecules were fabricated and functionalized following the
above-mentioned anodization and silanization protocols. These
Figure 3. Sensing concept used to establish the binding aﬃnity between HSA and indomethacin molecules by combining HSA-functionalized NAA-
RFs and RIfS. (a) Representative RIfS spectrum of a NAA-RF (TP = 650 s, JOffset = 0.42 mA cm
−2, and tpw = 0 min) showing the areas in the
spectrum used to establish changes in λPeak and OTeff associated with binding between HSA and indomethacin molecules. (b) Schematic illustration
describing the reversible binding event between HSA and indomethacin molecules with adsorption and desorption stages after injection of
indomethacin analytical solutions and fresh PBS, respectively. (c, d) Representative real-time measurements for ΔλPeak and ΔOTeff showing the shifts
in the position of the characteristic peak position and changes in the eﬀective optical thickness of NAA-RFs during the diﬀerent stages (blue and red
arrows indicate areas where ΔλPeak and ΔOTeff undergo blue and red shifts, respectively): (i) PBS baseline, (ii) GTA activation, (iii) PBS washing,
(iv) HSA immobilization, (v) PBS washing and PBS−EtOH baseline, (vi) indomethacin detection in PBS−EtOH, and (vii) PBS−EtOH washing
(note the example corresponding to a NAA-RF produced with TP = 750 s and JOffset = 0.42 mA cm
−2). (d) Detail of the absorption and desorption
stages (red square in parts c and d) for ΔλPeak and ΔOTeff vs time as a function of the concentration of indomethacin (1, 2, 3, 4, and 5 mM).
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samples were used to assess the binding aﬃnity between HSA
molecules immobilized onto NAA-RFs and a set of drug model
molecules, including indomethacin, coumarin, sulfadymethox-
ine, warfarin, and salicylic acid. These sensing experiments were
performed according to the process shown in the Optical
Characterization section using ΔλPeak and ΔOTeff as sensing
parameters (vide supra).
Structural Characterization. The structural characteristics
of NAA-RFs were established by a ﬁeld emission gun scanning
electron microscope (FEG-SEM FEI Quanta 450). These
images were subsequently analyzed by ImageJ (public domain
program developed at the RSB of the NIH) in order to measure
the period length in the diﬀerent NAA-RF structures.49
All the aforementioned experiments were repeated three
times with freshly modiﬁed NAA-RFs and analytical solutions,
and the characteristic parameters were calculated as averages
and standard deviations.
■ RESULTS AND DISCUSSION
Structural Characterization and Optical Optimization
of NAA-RFs. The optical properties and sensing performance
of NAA-RFs are strongly dependent on the period thickness
(LTp) (Figure 1b). Figure 1c shows representative cross-section
and top view images of NAA-RFs. These photonic structures
are composed of stacked layers of nanopores with sinusoidally
modiﬁed porosity in depth, which are generated by the
sinusoidal fabrication process described above. Figure 2a shows
cross-section SEM images with magniﬁed views of the NAA-
RFs used in this study, which were produced using nine
diﬀerent combinations of TP and JOffset (see Table 1). Digital
images of these photonic ﬁlms reveal that the interferometric
color, an optical property established by the position of the
characteristic reﬂection peak (λPeak), undergoes a red shift
toward longer wavelengths when TP and JOffset increase (Figure
2b).40 SEM image analysis reveals that LTp increases linearly
with the anodization period and the anodization oﬀset (Figure
2c,d). Nevertheless, we found slight diﬀerences in the
dependence of LTp with TP and JOffset. As Figure 2c shows,
the longer the anodization period is, the stronger the
dependence is for LTp on JOffset. The slope of the ﬁtting line
for the dependence of LTp on JOffset for TP = 650, 700, and 750 s
was found to be 135 ± 50, 272 ± 23, and 365 ± 4 nm (mA
cm−2)−1, respectively. Figure 2d shows the linear ﬁttings
describing how LTp varies with TP for the diﬀerent values of
JOffset. This graph reveals that the dependence of LTp on TP for
JOffset = 0.14, 0.28, and 0.42 mA cm
−2 was 0.0162 ± 0.04, 0.477
± 0.04, and 0.680 ± 0.10 nm s−1, respectively.
Optimization of Sensing Performance of HSA-
Modiﬁed NAA-RFs Combined with RIfS. The above-
mentioned NAA-RFs (Table 1) were modiﬁed with human
serum albumin and used as sensing platforms to establish the
binding aﬃnity between immobilized HSA and indomethacin
molecules as a function of the fabrication parameters (i.e., TP
and JOffset). Indomethacin is commonly used as a prescription
drug to reduce stiﬀness, fever, pain, and swelling. This drug was
used as a model drug molecule due to its well-known aﬃnity
toward HSA and other serum proteins. In this study, two
sensing parameters were used in order to establish the most
sensitive NAA-RF structures toward indomethacin molecules:
namely, (i) shifts in the characteristic reﬂection peak (ΔλPeak)
and (ii) changes in the eﬀective optical thickness of the ﬁlm
(ΔOTeff). Whereas the former parameter was established by
following the position of λPeak in the RIfS spectrum of NAA-
RFs, the latter was obtained by applying fast Fourier transform
to the RIfS spectrum of NAA-RFs.50 Figure 3a (inset) shows a
schematic illustration of a NAA rugate ﬁlter and the interfering
light beams at the diﬀerent interfaces forming these photonic
crystal structures. The reﬂectivity spectrum of NAA-RFs is
derived from two sources: namely, (i) the interference of light
from all layers of the multilayered NAA-RF structure and (ii)
the Fabry−Peŕot interference spectrum produced by the
reﬂections of light at the interfaces bordering the NAA-RF
ﬁlm.50 As a result, the RIfS spectrum of NAA-RFs displays a
narrow and well-deﬁned characteristic reﬂection peak, which
corresponds to the photonic stop band of the photonic crystals,
and small sideband fringes produced by the Fabry−Peŕot
interference in the photonic ﬁlm (Figure 3a). In our
experiments, the characteristic reﬂection peak (λPeak) was
separated from the Fabry−Peŕot fringes region in order to
apply an FFT to the selected region and estimate the eﬀective
optical thickness (OTeff) of the ﬁlm.
50 Both optical parameters
were used as sensing references to establish the most sensitive
NAA-RFs structures toward indomethacin molecules. Figure 3b
shows a schematic illustration of the sensing approach used in
our study to establish the binding aﬃnity between drug
molecules and HSA-modiﬁed NAA-RFs. Figure 3c,d displays
examples of this process using HSA-modiﬁed NAA-RFs and
RIfS with ΔλPeak and ΔOTeff as the sensing reference
parameters, respectively. This process is divided into three
stages: (i) chemical activation of amine (−NH2) groups present
on the surface of NAA by GTA, (ii) immobilization of HSA
molecules on the surface of activated NAA-RFs, and (iii)
adsorption−desorption of drug molecules from HSA-modiﬁed
NAA-RFs. First, fresh PBS (pH 7.4) solution was ﬂowed at a
rate of 100 μL min−1 through the ﬂow cell, where APTES-
functionalized NAA rugate ﬁlters were placed. A stable baseline
for ΔλPeak and ΔOTeff was achieved after 15 min (i, Figure
3c,d). After this, a 2.5 v% GTA solution in PBS was ﬂowed
through the system for 30 min in order to activate the amine
groups present on the inner surface of NAA-RFs (ii, Figure
3c,d). In this stage, ΔλPeak and ΔOTeff underwent a red shift
due to the interaction between activated amine groups present
on the inner surface of NAA-RFs and GTA molecules. Fresh
PBS solution was ﬂowed again after GTA activation for 15 min
in order to remove physisorbed GTA molecules from the
surface of NAA-RFs. As a result, ΔλPeak and ΔOTeff decreased
slightly during this process (iii, Figure 3c,d). Next, a 1 mg mL−1
solution of HSA in PBS was injected into the system and
ﬂowed at 100 mL min−1 for 1 h (iv, Figure 3c,d). A marked red
shift was observed both in sensing parameters as a result of the
binding event between GTA-activated APTES-modiﬁed NAA-
RFs and HSA molecules.
Then, fresh PBS solution was ﬂowed through the ﬂow cell in
order to wash away physisorbed HSA molecules (v, Figure
3c,d). Prior to injection of indomethacin analytical solutions, a
baseline in a modiﬁed PBS solution containing EtOH 5 v% was
obtained for 15 min in order to compensate the addition of
ethanol to improve the solubility of indomethacin, which is a
highly hydrophobic therapeutic. The binding interaction
between HSA and indomethacin molecules present in the
PBS solution resulted in a sharp red shift both in ΔλPeak and
ΔOTeff (vi, Figure 3c,d), which continued until the HSA
molecules present in the inner surface of NAA-RFs were
saturated by indomethacin molecules (i.e., equilibrium stage =
end of vi, Figure 3c,d). After this, fresh PBS solution containing
5 v% EtOH was ﬂowed through the system in order to desorb
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indomethacin from HSA molecules (vii, Figure 3c,d). Note that
the binding event between indomethacin molecules and HSA
molecules is a reversible reaction. Therefore, both ΔλPeak and
ΔOTeff underwent a blue shift until the original baseline (i.e., vi,
Figure 3c,d) was reached. A summary of the obtained results
for ΔλPeak and ΔOTeff for each analytical solution of
indomethacin (1, 2, 3, 4, and 5 mM) are displayed in Figure
3e,f. This process is characterized by two stages: (i) adsorption
stage, when the analytical solution of drug is injected into the
ﬂow cell, and (ii) desorption stage, when fresh PBS solution is
ﬂowed through the ﬂow cell and drug molecules are released
from HSA. The total changes in ΔλPeak and ΔOTeff can be
calculated as indicated in Figure 3e,f.
Figure 4a,b shows the linear ﬁttings for ΔλPeak and ΔOTeff as
a function of the concentration of indomethacin for the
diﬀerent NAA-RFs structures used in this study (Table 1).
These graphs show that ΔλPeak and ΔOTeff have a linear
dependence with the concentration of indomethacin. A linear
ﬁtting between ΔλPeak and ΔOTeff and the concentration of
indomethacin makes it possible to estimate the sensitivity, S
Figure 4. Optical optimization and establishment of binding aﬃnity between drug molecules and HSA-modiﬁed NAA-RFs by RIfS. (a) Linear ﬁtting
lines showing the linear dependence between ΔλPeak and the diﬀerent concentrations of indomethacin (1, 2, 3, 4, and 5 mM) for each type of NAA-
RF. (b) Linear ﬁtting lines showing the linear dependence between ΔOTeff and the diﬀerent concentrations of indomethacin (1, 2, 3, 4, and 5 mM)
for each type of NAA-RF. (c) Contour map showing the distribution of sensitivity (S) as a function of the fabrication parameters (i.e., TP and JOffset)
for ΔλPeak calculated from part a. (d) Contour map showing the distribution of sensitivity (S) as a function of the fabrication parameters (i.e., TP and
JOffset) for ΔOTeff calculated from part b. (e) Linear ﬁtting lines showing the dependence between ΔλPeak and the diﬀerent concentrations of the
drugs assessed in this study for NAA-RF750−0.42. (f) Linear ﬁtting lines showing the dependence between ΔOTeff and the diﬀerent concentrations of
the drugs assessed in this study for NAA-RF750−0.14.
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(i.e., slope of the ﬁtting line), the low limit of detection, LLoD
(i.e., calculated as 3σ), and the linearity, R2 (i.e., correlation
coeﬃcient of the ﬁtting line), for each NAA-RF. The obtained
results, summarized in Table S1 (Supporting Information),
reveal that the NAA-RF structures with the highest sensitivity
for ΔλPeak and ΔOTeff were NAA-RF750−0.42 (S = 0.66 ± 0.03
nm mM−1, LLoD = 0.65 ± 0.02 mM, and R2 = 0.985) and
NAA-RF750−0.14 (S = 91.1 ± 3.4 nm mM
−1, LLoD = 0.41 ± 0.03
mM, and R2 = 0.994), respectively. Figure 4c,d shows contour
maps displaying the dependence of S on the fabrication
parameters (TP and JOffset) for ΔλPeak and ΔOTeff. These graphs
denote that the distribution of S with TP and JOffset is fairly
homogeneous for both the cases (i.e., ΔλPeak and ΔOTeff) since
the distribution of color ﬁelds (i.e., increment in S) is
concentrically homogeneous around the minimum values,
which are located at TP = 700 s and JOffset = 0.14 mA cm
−2
for ΔλPeak and ΔOTeff. However, although the lines between
color ﬁelds are closer to each other in a similar manner, it is
worth noting that contour lines in ΔλPeak are much closer
around the proximity of the maximum value (TP = 750 s and
JOffset = 0.42 mA cm
−2) than those of ΔOTeff, indicating a much
stronger dependence of S on TP and JOffset. In order to gain a
more objective insight into the dependence of S on TP and
JOffset, we performed an ANOVA analysis for the sensitivity
obtained by measuring both sensing parameters (ΔλPeak and
ΔOTeff).
The ANOVA analysis (Table 2) was performed using the
values of S measured from ΔλPeak and ΔOTeff, and the values of
each parameter were estimated using the equations shown in
Table S2 (Supporting Information). In this analysis, the
hypotheses H0, H1, and H2 are assessed by comparing the
value of F0 (i.e., test statistic calculated from the ANOVA table)
and the corresponding value of the F-distribution for a
signiﬁcance level of 95%. Our analysis for S obtained from
ΔλPeak denotes that the hypotheses H0 and H1 are both rejected
since the individual eﬀects of these anodization parameters are
signiﬁcant (i.e., 166.9 and 66.9 > F(0.05;2;27) = 3.4, respectively).
Therefore, the alternative hypotheses H0* and H1* are
accepted. This analysis also reveals that the interaction between
TP and JOffset (TP·JOffset) is signiﬁcant as well because 119.0 >
F(0.05;4;27) = 2.7. Thus, the hypothesis H2 is also rejected and the
alternative hypothesis H2* accepted. As a result, it is concluded
that all the fabrication parameters (i.e., TP, JOffset, and their
interaction TP·JOffset) have a signiﬁcant eﬀect over S. Never-
theless, the magnitudes of H0*, H1*, and H2* have diﬀerent
weight over the studied variable S, being 47.3%, 19.0%, and
33.7% for TP, JOffset, and their interaction TP·JOffset, respectively.
Hence, S is found to have a stronger dependence on TP when
ΔλPeak is used as the sensing parameter.
As far as the ANOVA analysis on S obtained from ΔOTeff is
concerned, it shows that the hypotheses H0 and H1 are both
rejected as the individual eﬀects of TP and JOffset are both
signiﬁcant (i.e., 51.7 and 36.6 > F(0.05;2;27) = 3.4, respectively).
As a result, the alternative hypotheses H0* and H1* are
accepted. Furthermore, it is found that the interaction between
TP and JOffset (TP·JOffset) is also signiﬁcant since 84.8 > F(0.05;4;27)
= 2.7. Therefore, the hypothesis H2 is rejected and the
alternative hypothesis H2* accepted. In this case, it is
established that TP, JOffset, and their interaction TP·JOffset all
have a signiﬁcant eﬀect over S. However, the magnitudes of
H0*, H1*, and H2* have weights of 29.9%, 21.1%, and 49.0%.
Therefore, S has a more marked dependence on the interaction
TP·JOffset when ΔOTeff is used as the sensing parameter.
Assessment of Binding Aﬃnity between Drugs and
HSA-Modiﬁed NAA-RFs by RIfS. A set of the most sensitive
NAA-RFs structures toward indomethacin molecules (NAA-
RF750−0.42 and NAA-RF750−0.14 for ΔλPeak and ΔOTeff,
respectively) were used in order to establish the binding
aﬃnity between a set of drugs (i.e., indomethacin, coumarin,
sulfadymethoxine, warfarin, and salicylic acid) and HSA
molecules by RIfS using ΔλPeak and ΔOTeff as sensing
parameters. This set of experiments was carried out following
the above-mentioned protocol (vide supra) in a ﬂow cell where
ﬁve analytical solutions of each drug (1, 2, 3, 4, and 5 mM)
were ﬂowed at a constant rate (100 μL min−1). The obtained
results for ΔλPeak and ΔOTeff are summarized in Table 3 and
Figure 4e,f, respectively. ΔλPeak establishes that the binding
Table 2. Summary of the ANOVA Analysis Performed in
Our Study To Establish the Most Optimal NAA-RF
Structures As a Function of the Fabrication Parameters (TP
and JOffset)
source of variance SS DF MS F0
Sensing Parameter ΔλPeak
TP (s) 0.1032 2 0.0516 166.9
JOffset (mA cm
−2) 0.0414 2 0.0207 66.9
TP·JOffset (s mA cm
−2) 0.1472 4 0.0368 119.0
model 0.2917 8 0.0365 117.9
error 0.0056 18 3.0922
total 0.2973 26
Sensing Parameter ΔOTeff
TP (s) 1688.9 2 844.4 51.7
JOffset (mA cm
−2) 1195.1 2 597.6 36.6
TP·JOffset (s mA cm
−2) 5545.6 4 1386.4 84.8
model 8429.6 8 1053.7 64.5
error 294.2 18 16.3
total 8723.9 26
Table 3. Summary of Binding Aﬃnity between Drug Molecules and HSA-Functionalized NAA-RFs Obtained from ΔλPeak (NAA-
RF750‑0.42) and ΔOTeff (NAA-RF750‑0.14) and Comparison with the Binding Aﬃnity Reported in the Literature
sensing parameter
ΔλPeak ΔOTeff
drug S (nm mM−1) level S (nm mM−1) level literaturea level
indomethacin 0.560 ± 0.067 M 89.8 ± 2.3 H H
sulfadymethoxine 0.027 ± 0.005 L 5.5 ± 0.7 M H
warfarin 0.138 ± 0.024 M 18.4 ± 3.2 H H
coumarin 0.045 ± 0.012 L 8.3 ± 1.7 M M
salicylic acid 4.850 ± 0.317 H 4.9 ± 0.3 M M
aValues obtained from ref 9.
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aﬃnity between HSA and the aforementioned set of drugs
follows the order salicylic acid (S = 4.850 ± 0.317 nm mM−1) >
indomethacin (S = 0.560 ± 0.067 nm mM−1) > warfarin (S =
0.138 ± 0.024 nm mM−1) > coumarin (S = 0.045 ± 0.012 nm
mM−1) > sulfadymethoxine (S = 0.027 ± 0.005 nm mM−1). In
contrast, ΔOTeff establishes that the binding aﬃnity between
these drugs and HSA molecules follows the order indomethacin
(S = 89.8 ± 2.3 nm mM−1) > warfarin (S = 18.4 ± 3.2 nm
mM−1) > coumarin (S = 8.3 ± 1.7 nm mM−1) >
sulfadymethoxine (S = 5.5 ± 0.7 nm mM−1) > salicylic acid
(S = 4.9 ± 0.3 nm mM−1).
Previous studies have reported that, whereas the binding
aﬃnity between indomethacin, sulfadymethoxine, warfarin, and
HSA molecules is high, coumarin and salicylic acid present an
interaction with medium strength toward this plasma protein.9
Our results using ΔλPeak as the sensing parameter establish
salicylic acid as a drug molecule with high aﬃnity toward HSA
molecules, whereas indomethacin and warfarin have medium
aﬃnity, and coumarin and sulfadymethoxine present a low
aﬃnity toward HSA. However, indomethacin and warfarin have
high aﬃnity toward HSA molecules, and coumarin, sulfadyme-
thoxine, and salicylic acid are found to be drug molecules with
medium aﬃnity when ΔOTeff is used as the sensing parameter.
These results reveal a higher degree of agreement between the
results obtained by benchmark techniques9 and those obtained
in this study by ΔOTeff. Therefore, it can be concluded that
ΔOTeff is a more reliable sensing parameter than ΔλPeak to be
used in the proposed sensing system combining NAA-RFs and
RIfS.
■ CONCLUSIONS
This study has reported on an approach that aims to assess the
binding aﬃnity between drug molecules and human serum
albumin by combining HSA-modiﬁed NAA-RFs with RIfS.
First, we carried out a systematic analysis of the structural
features and optical properties of NAA-RFs produced by
sinusoidal pulse anodization. These photonic crystal structures
present two characteristic optical parameters, the characteristic
reﬂection peak (λPeak), and the eﬀective optical thickness of the
ﬁlm (OTeff), which can be readily used as sensing parameters. A
set of nine NAA-RFs were used to establish the most sensitive
structures toward indomethacin molecules, a model drug, as a
function of two fabrication parameters (i.e., TP, anodization
period, and JOffset, anodization oﬀset). A design of experiment
strategy made it possible to establish the eﬀect of these
anodization parameters on the sensitivity of HSA-modiﬁed
NAA-RFs using two sensing parameters, that is, shifts in the
characteristic reﬂection peak (ΔλPeak) and changes in the
eﬀective optical thickness of the ﬁlm (ΔOTeff). An ANOVA
analysis established that the anodization period, the anodization
oﬀset, and their interaction have all signiﬁcant eﬀects on the
sensing performance of NAA-RFs for both sensing parameters
(i.e., ΔλPeak and ΔOTeff). Nevertheless, whereas TP was found
to be the parameter with the most signiﬁcant inﬂuence over S
in the case of ΔλPeak, the interaction TP·JOffset was the parameter
with the strongest inﬂuence over the sensitivity of NAA-RFs for
ΔOTeff. Our analysis also revealed that the most sensitive
structures toward indomethacin molecules were NAA-
RF750−0.42 and NAA-RF750−0.14 for ΔλPeak and ΔOTeff,
respectively. Subsequently, we used these NAA-RF structures
in order to establish the binding aﬃnity between a set of drugs
(i.e., indomethacin, coumarin, sulfadymethoxine, warfarin,
salicylic acid) and HSA molecules. We found that, in the case
of NAA-RFs, the binding aﬃnity between drug molecules and
HSA is dependent on the sensing parameter used. Whereas
ΔλPeak established salicylic acid as the drug molecule with the
highest aﬃnity toward HSA molecules, indomethacin was
found to be the drug with the strongest aﬃnity when ΔOTeff
was used as the sensing parameter. Although the low limit of
detection achieved by our system is slightly higher than that of
benchmark techniques such as SPR, the obtained results are
certainly promising, and there is still margin for improvement
by further optimization strategies. The proposed sensing system
combining HSA-modiﬁed NAA-RFs and RIfS provides a
reliable means of assessing the binding aﬃnity of drugs with
a set of features such as portability, low cost, and easy operation
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(14) Birkert, O.; Tünnemann, R.; Jung, G.; Gauglitz, G. Anal. Chem.
2002, 74, 834−840.
(15) Belge, G.; Beyerlein, D.; Betsch, C.; Eichhorn, K. J.; Gauglitz,
G.; Grundke, K.; Voit, B. Anal. Bioanal. Chem. 2002, 374, 403−411.
(16) Gauglitz, G.; Brecht, A.; Kraus, G.; Mahm, W. Sens. Actuators, B
1993, 11, 21−27.
(17) Curtis, C. L.; Doan, V. V.; Credo, G. M.; Sailor, M. J. J.
Electrochem. Soc. 1993, 140, 3492−3494.
(18) Lin, V. S. Y.; Motesharei, K.; Dancil, K. S.; Sailor, M. J.; Ghadiri,
M. R. Science 1997, 278, 840−843.
(19) Masuda, H.; Fukuda, K. Science 1995, 268, 1466−1468.
(20) Masuda, H.; Hasegwa, F. J. J. Electrochem. Soc. 1997, 144, L127−
L130.
(21) Masuda, H.; Yada, K.; Osaka, A. Jpn. J. Appl. Phys. 1998, 37,
L1340−L1342.
(22) Nielsch, K.; Choi, J.; Schwirn, K.; Wehrspohn, R. B.; Gösele, U.
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